RT info:eu-repo/semantics/article
T1 Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
A1 Palacios-Ramirez, Roberto
A1 Lima-Posada, Ixchel
A1 Bonnard, Benjamin
A1 Genty, Marie
A1 Fernandez-Celis, Amaya
A1 Hartleib-Geschwindner, Judith
A1 Foufelle, Fabienne
A1 Lopez-Andres, Natalia
A1 Bamberg, Krister
A1 Jaisser, Frederic
K1 CKD-chronic kidney disease; fibrosis; inflammation; kidney; mineralocorticod receptors
AB Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven their clinical efficacy in diabetic kidney disease with preclinical data suggesting that they may also be efficient in non-diabetic chronic kidney disease associated to metabolic diseases. In the present study we developed a novel mouse model combining severe nephron reduction and High Fat Diet challenge that led to chronic kidney disease with metabolic alterations. We showed that the Mineralocorticoid Receptor antagonist canrenoate improved metabolic function, reduced albuminuria and prevented the synergistic effect of high fat diet on renal fibrosis and inflammation in chronic kidney disease mice.
YR 2022
FD 2022-04-07
LK https://uvadoc.uva.es/handle/10324/65927
UL https://uvadoc.uva.es/handle/10324/65927
LA spa
NO Front Physiol. 2022 Apr 7:13:859812.
NO Producción Científica
DS UVaDOC
RD 28-nov-2024